Latest News and Press Releases

Quanta presented positive Phase 1 data for QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with advanced cancer, including CRC, PDAC

RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative,...

– 25-year industry veteran Vanessa L. Jacoby appointed CBO and CFO, bringing financial and strategic leadership – – Enrollment initiated in dose expansion cohorts in Phase 1 clinical trial of...

- Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in...

SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, oral...

– IND for QTX3544 is third for Quanta within one year – – Initiated combination portion of Phase 1 clinical trial of QTX3046, an oral KRASG12D-selective dual ON/OFF state allosteric inhibitor, with...

Quanta is advancing 2 clinical trials from its pipeline of KRAS G12D-focused drug candidates, as monotherapy and combination with EGFR inhibitors

–Strong anti-tumor activity, favorable oral bioavailability and drug-like properties demonstrated in preclinical models – –Data support ongoing IND-enabling studies for planned clinical...

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers, today...

QTX3034, G12D-preferring multi-KRAS inhibitor, IND received clearance by US FDA to begin Phase 1 study; planned for 1Q24; and other pipeline updates